A biomedical device is disclosed. The biomedical device includes a polymerization product of a biomedical device-forming mixture containing (a) one or more grafted glycosaminoglycan polymers including a glycosaminoglycan having a polymer backbone and one or more side chains comprising an ethylenically unsaturated reactive-containing residue grafted onto the polymer backbone, and (b) one or more non-silicone biomedical device-forming monomers.

The disclosure relates to compositions comprising crosslinked hyaluronic acid physically mixed with collagen. Also contemplated are methods of improving an aesthetic quality of an anatomic feature of a human being.

Described herein are compounds of Formula (I), polymers and implantable elements comprising compounds of Formula (II), and compositions and methods of use thereof. In particular, the compounds, modified polymers, implantable elements and related compositions may be used in methods for the prevention and treatment of a disease, disorder or condition in a subject.

A graft copolymer comprising: a core polymer comprising a crosslinked or non-crosslinked polysaccharide, a plurality of primary graft polymers covalently grafted to the core polymer, a plurality of secondary graft polymers covalently grafted to each primary graft polymer, an injectable dermal aesthetic formulation comprising such a graft copolymer and a method of preparing such a graft copolymer.

The invention relates to a method for the stabilization of a polysaccharide (hyaluronic acid) with a biomolecule—amino acid—through crosslinking, to generate a bionic hydrogel based on physiological building blocks for applications in regenerative medicine. The designed biosimilar hydrogel is intended to be used in regenerative medicine for the purpose of regenerate, rejuvenate and/or restore the structure or function of impaired or damaged tissues, and to promote healing. The manufacture method is composed of a single step that includes mixing L-lysine and hyaluronic acid sodium salt in an aqueous saline solution with either EDC/NHS as coupling agent.

A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

A process for producing a composition comprising a crosslinked hydrogel is proposed. The process comprises providing a container body (2), wherein the container body (2) has a body inner wall (21) and a body outer wall (22), wherein the body inner (21) wall is configured to be tempered, filling of a fluid (7) comprising at least a mixture of a polymer and water into the container body (2), and agitating the fluid. For crosslinking of the fluid (7), a container insert (3) is provided, the container insert (3) having an insert outer wall (32) which is configured to be tempered and a container assembly (1) is formed by inserting the container insert (3) into the container body (2) so that the insert outer wall (32) of the container insert (3) and the body inner wall (21) of the container body (2) are separated by a gap (9) of constant width and define a volume (6) for receiving the fluid (7). Crosslinking of the fluid (7) is then performed while tempering the insert outer wall (32) and the body inner wall (21) to form a crosslinked hydrogel.

The present disclosure presents hydrogel compositions for use in the treatment of an ocular disorder (e.g., a retinal disease) and methods of treating an ocular disorder in a subject in need thereof with the hydrogel compositions. The hydrogel compositions can include hydroxyphenylpropionic acid (gelatin-HPA), hyaluronic acid-tyramine (HA-Tyr), a catalyzer (e.g., horseradish peroxidase (HRP)), a cell, a crosslinker (e.g., hydrogen peroxide), or any combination thereof. The methods include administering a therapeutically effective amount of a composition into an eye of the subject, wherein the composition includes any of the hydrogel compositions of the disclosure.

The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug.

A sulfhydryl modified hyaluronic acid has a high mercaptan content, and a small change in the molecular mass of the main chain molecule, and has a significantly improved viscosity, water retention, and oxidation resistance. It is prepared from hyaluronic acid modified by acryl-based compounds and polysulfhydryl compounds by means of the Michael addition reaction of mercaptan and conjugated double bonds. The preparation method can flexibly control the structure and composition of a synthesized product, the type and content of the terminal functional group of a large number of compound molecules, etc. The use of a reagent having high biocompatibility effectively controls the production cost and reduces the toxicity during the synthesis.